Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Operating expense | 1.7M | 15.4% |
| Net Income | -2.3M | 2.5% |
| EBITDA | -1.7M | 15.1% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 2.1M | 44.7% |
| Total Liabilities | 4.3M | 14.4% |
| Shares Outstanding | 7,300 | 301.9% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -1.3M | 37.8% |
| Cash from financing | -130,000 | 102.8% |
EPS
Financial Highlights for Oragenics in Q2 '25
Operating Expenses for this period were 1.7M, showing a -15.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -2.3M, showing a -2.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -1.7M, showing a 15.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Oragenics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income.
